secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001104659-23-000640
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm promotes Dr. Lindborg to Co-CEO; Dr. Kern retires as CMO with separation package
--------------------------------------------------------------------------------

- Dr. Stacy Lindborg appointed Co-CEO, base salary $500K, annual bonus 40% of salary, 250K RSU equity grant.
- Dr. Ralph Kern retires as President and CMO effective Jan 20, 2023; receives $250K severance, 150K shares, $125K prorated bonus.
- Unvested equity that would vest within six months accelerates for Dr. Kern upon separation.
- Dr. Kern to join Scientific Advisory Board at $450/hour, up to 10 hours/month, for two-year term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923000640/0001104659-23-000640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923000640/tm231494d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-000640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer